Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463303 | 0.91 | LMNA (0.45) | DRD2F10KDM4ECHRM3LMNA | |
| SCHEMBL2462033 | 0.90 | LMNA (0.46) | DRD2F10KDM4ECHRM3LMNA | |
| SCHEMBL2462459 | 0.90 | LMNA (0.46) | DRD2F10KDM4ECHRM3LMNA | |
| SCHEMBL2462310 | 0.90 | LMNA (0.46) | DRD2F10KDM4ECHRM3LMNA | |
| SCHEMBL2461533 | 0.89 | DRD2 (0.45) | DRD2F10KDM4ECHRM3SMN1; SMN2 | |
| SCHEMBL2462607 | 0.89 | DRD2 (0.45) | DRD2F10KDM4ECHRM3SMN1; SMN2 | |
| SCHEMBL2461530 | 0.89 | DRD2 (0.45) | DRD2F10KDM4ECHRM3SMN1; SMN2 | |
| SCHEMBL2460309 | 0.88 | DRD2 (0.44) | DRD2F10KDM4ECHRM3SMN1; SMN2 | |
| SCHEMBL2459300 | 0.86 | KMT2A (0.42) | DRD2F10CHRM3SMN1; SMN2 | |
| SCHEMBL2460567 | 0.85 | KMT2A (0.41) | DRD2F10KDM4ECHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | DRD2 4716/4885F10 3668/4885KDM4E 1461/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | DRD2 4716/4885F10 3668/4885KDM4E 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.